BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
40
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PADCEV (enfortumab vedotin) is an antibody-drug conjugate (ADC) that targets Nectin-4, a cell surface protein expressed on urothelial carcinoma cells. It is indicated for locally advanced or metastatic urothelial carcinoma in patients who have previously received a PD-L1 inhibitor and a platinum-containing chemotherapy. The drug works by binding to Nectin-4 and delivering a microtubule-disrupting payload intracellularly.
$4MPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization, suggesting mature market penetration with stable commercial operations and established team infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (40)
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Started Jun 2026
37 enrolled
Advanced Urothelial CancerMetastatic Urothelial Carcinoma
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Started May 2026
390 enrolled
Urothelial CancerUrinary Bladder Neoplasms
Study of EV for Recurrent Endometrial Carcinoma
Started Apr 2026
12 enrolled
Endometrial Cancer
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Started Mar 2026
240 enrolled
Muscle-invasive Bladder Cancer
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Started Mar 2026
132 enrolled
Urothelial CancerAdvanced/Metastatic Urothelial CancerUrothelial Carcinoma
Worked on PADCEV at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.